Table 5.
Sensitivity and specificity of additional CC groupings tested during refinement phase of the trial (Phase 6).
| Site 1 | Site 2 | Site 3 | |||||||
|---|---|---|---|---|---|---|---|---|---|
| Sensitivity | Specificity | PPV | Sensitivity | Specificity | PPV | Sensitivity | Specificity | PPV | |
| Initial CC grouping without null | 87.9% | 86.8% | 27.5% | Not completed | 91.2% | 91.9% | 32.9% | ||
| Refined grouping with highest specificity (with associated sensitivity)* | 43.5% | 96.1% | 37.6% | 75.6% | 95.8% | 54.3% | 75.8% | 97.2% | 58.9% |
| Refined grouping with highest specificity with sensitivity at least 90% | 91.8% | 85.9% | 26.1% | 90.4% | 92.6% | 45.7% | 90.0% | 95.8% | 52.8% |
*Of the combinations tested. Clinically-relevant combinations of CCs were created in order to improve specificity while main taining a high sensitivity.
CC: chief complaint